Furthermore, using the independent French dataset [23], we found that the significant survival benefit associated with higher expression of NFIB existed for patients with GBM, astrocytoma and glioma (Figure 2B–2D). Here, NFIB is linked to astrocytoma (excluding glioblastoma).